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Abstract
Background: The widespread adoption of electronic health records provides new opportunities to better predict
which patients are likely to suffer a stroke. Using electronic health records, we assessed the correlation of different
laboratory tests to future occurrences of a stroke.
Methods: We examined the electronic health records of 2.4 million people over a two year time span. These
records contained 26,964 diagnoses of stroke. Using Cox regression analysis, we measured whether any one of
1796 different laboratory tests were effectively correlated with a future diagnosis of stroke.
Results: We identified 38 different laboratory tests that had significant short-term (two year) prognostic value for a
future diagnosis of stroke. For each of the 38 laboratory tests we also compiled the Kaplan-Meier survival curve, and
relative risk ratio that the test confers.
Conclusion: Several dozen laboratory tests are effective short-term correlates of stroke.
Background
Several stroke risk scores have been developed to iden-
tify those with the highest risk of stroke [1–4]. These
stroke risk scores are mostly based on information one
could collect when taking a patient’s medical history.
Identification of those most at risk for developing stroke
would allow focused education on both reducing risk
factors and recognizing signs of a stroke. Early recogni-
tion and treatment of stroke can substantially reduce
both the direct and indirect costs of a stroke [5].
Electronic health records (EHRs) are rapidly being
adopted by medical providers, and are now used by the
majority of office-based physicians and hospitals in the
US [6, 7]. These EHRs do not always provide easily com-
putable information regarding a patient’s medical his-
tory, but do an excellent job of providing discrete data
from laboratory tests, imaging studies, and pharmacy re-
cords. Thus an opportunity exists to develop a stroke
risk score that one could compute from discrete data
contained in EHRs.
The best known stroke risk score is the Framingham
Stroke Risk Profile, developed as part of the Framingham
Heart Study [1, 2]. This risk score was based on an ana-
lysis of 472 stroke events. The score computes the prob-
ability of developing a stroke within the next 10 years
based on age, sex, systolic blood pressure, along with
categorical factors disclosed by the patient when taking
a medical history such as whether the patient smokes
cigarettes or has been diagnosed with diabetes or atrial
fibrillation.
Two other stroke risk scores have been published.
First, a short term (3 year) measure of stroke risk was
developed based on 188 strokes observed in data col-
lected by the Cardiovascular Health Study [8, 9]. Second,
a long term (two decades) stroke risk score was de-
veloped based on 282 strokes observed in a popula-
tion of municipal employees in Israel as part of the
Israel Ischemic Heart Disease Project [4].
Several different health outcomes have been predicted
from electronic health records [10]. Examples include:
the identification of drug-drug interactions [11, 12],
computation of the genetic risk for diabetes [13], identi-
fication of diabetes medication that significantly in-
creased risk of myocardial infarction [14] and prediction
of the patients’ future risk of receiving a diagnosis of do-
mestic abuse [15].
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The purpose of this study is to identify laboratory tests
that effectively correlate with the occurrence of stroke.
This study is based on 26,954 observations of stroke in a
one-year period from the electronic health records of a
large managed care organization.
Methods
We tested which laboratory tests were correlated with a
future diagnosis of stroke using Cox Regression,
controlling for age and sex differences. We used a
database of electronic health records from Kaiser
Permanente containing one year of patient records
containing records for 2.4 million patients, 26,964 of
whom received a diagnosis of stroke during the one
year period. We compared laboratory test results
that the 26,964 patients received several months be-
fore their diagnosis of stroke with the laboratory test
results that the patients who never received a stroke
diagnosis. From this comparison, we identified la-
boratory tests that had significantly different results
in the two populations: those who would have a
stroke within a few months and those who would
not.
Kaiser Permanente (KP) is a non-profit health plan
with 9.6 million members, and the largest region is
Southern California with over 3.8 million members. KP
offers comprehensive health care including outpatient
and inpatient care, laboratory services, and pharmacies.
Kaiser Permanente implemented electronic health re-
cords before 2009 [16, 17].
This is a retrospective data-only study. All data for
this study were selected from members of Kaiser
Permanente’s Southern California Health Plan who
had continuous coverage over a recent one-year time
span inclusive of 2013. Subjects were not systematic-
ally tested, but only received specific tests indicated
by their medical condition. We limited the subject
pool to only those patients that had received any
form of care from Kaiser Permanente during 2013, in-
cluding laboratory-only visits and both inpatient and
outpatient encounters. Furthermore, we included only
one laboratory result per type of test per month. We
limited the data to one result per month to prevent
over counting individuals who may be sampled more
frequently, which would bias our results. Only
discrete data elements of demographics, diagnoses, la-
boratory tests, and EKGs were extracted and analyzed,
from which all Protected Health Information (PHIs)
were removed during data extraction.
Overall, the study included 2,412,213 individuals. Of
these 51 % (1,239,559) were female. The birth-year dis-
tribution of this population is shown in Fig. 1 and the
frequency of self-reported race/ethnicity categories are
shown in Additional file 1: Table S1.
ICD-9 Codes
Diagnoses were identified by ICD-9 codes, and we in-
cluded diagnoses that were coded for encounters or
were added to problem lists during the time period. We
included both ischemic and hemorrhagic strokes, and in-
cluded all diagnoses with ICD-9 codes that began with
431, 433, and 434. The total number of strokes suffered
by the cohort during this time period was 26,964. 95.17 %
were ischemic strokes.
LOINC codes
Laboratory tests and other procedures are classified
using the Logical Observation and Identifiers Names
and Codes (LOINC) system [18, 19]. This system stan-
dardizes electronic records of medical laboratory results.
A total of 1796 LOINC codes were found in the Kaiser
Permanente database. We tested whether each of these
correlated with a future diagnosis of stroke. Of the
2,412,213 Southern California Kaiser Permanente mem-
bers during the time period analyzed, 1,406,413 (58 %)
had one or more LOINC record.
Cox regression
We asked whether any of the 1796 laboratory tests
had significant correlation with stroke. To determine
whether any significant correlation exists, we used
Cox proportional hazards model [20, 21]. The level of
significance was conservatively set at 10−2 divided by
the number of comparisons, 1796. We rounded this
quotient down to 10−6, which was set as the level of
significance. We supplied the patient’s age and sex as
covariates to each of the 1796 regressions. Therefore,
test results that are correlated with age alone will not
be identified as significant correlates with stroke. We
used the survival package in the R statistical software
package [22, 23] to perform the regression. More
Fig. 1 The age distribution of patients in the dataset
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advanced statistical approaches exist and could be ap-
plied to this problem [24].
We excluded some laboratory test results from our
analysis. Some laboratory tests are repeated frequently
on a patient. To prevent overweighting with these
tests, we only included one of these measurements
per month, using the median for a month of mea-
surements as that month’s value. Cox Regression as-
sumes independence between measurements, but we




Of the 1796 LOINC codes tested, 38 had a statisti-
cally significant correlation with a future diagnosis of
stroke, indicated by a p-value less than 10−6. Tests
with a positive correlation indicated that an increase
in the lab value saw an increased chance of stroke. A
negative number indicated that an increase in lab
value correlated with a decreased chance of stroke.
Laboratory tests that are significant correlates of
stroke can be seen in Table 1. Since each laboratory
test has a different mean and distribution of values,
we calculated an adjusted coefficient that shows the
change in the likelihood of stroke given a 1 % in-
crease in lab values.
Correlation
To test if some lab values were only effective correlates
of stroke because of their correlation to other laboratory
values, we measured the 741 pairwise correlation coeffi-
cients between the 38 different laboratory tests that were
statistically significant correlates of stroke. These correl-
ation measurements are shown in Additional file 1:
Table S2 and in the Additional file 2. The table shows
strong correlations between a few variables, most not-
ably between various types of cholesterol. These correla-
tions were calculated using the Pearson method, and
again using R.
Relative risk
We calculated the relative risk of each laboratory
value to determine how these laboratory values
change a patient’s risk of stroke. Several of the la-
boratory tests had non-linear relationships to stroke
risk, preventing us from using a linear model of risk.
Relative risk calculations require two distinct groups,
instead of a continuous scale, so patients were
grouped according to quartile. The relative risk com-
puted in Table 2 compares patients in the lowest
quartile (bottom 25 % of patients) to patients in the
top quartile (top 25 %). The 95 % confidence intervals
on the relative risk are also included.
Survival graphs
Kaplan-Meier survival graphs provide another measure-
ment of the impact of laboratory values on the chance of
stroke. The time until a stroke occurs is shown for each
quartile as well as the 5th and 95th percentile of records.
The laboratory test values that correspond to the indi-
cated percentiles are given in Table 3. Note that most
patients, regardless of lab values, did not suffer a stroke
during this time period, and thus the survival plots re-
main above 90 %.
Finally, we saw significant correlation in cholesterol
levels: total cholesterol, HDL, non-HDL and LDL.
Higher levels of all of these analytes were correlated with
a lower risk of stroke. A detailed graph showing the rela-
tionship between cholesterol levels and the risk of stroke
is shown in Fig. 2.
Discussion
We identified 38 tests that effectively correlate with
stroke. These 38 tests included three from electrocardio-
gram measurements, two from urine tests, and 33 from
blood, serum and/or plasma. Many of the 33 blood tests
are part of standard panels, including 12 that are typic-
ally included in (or calculated from) a comprehensive
metabolic panel and 14 from a complete blood count
with differential and 5 that are included in a lipid panel.
The other two blood tests are used to diagnose heart
failure (natriuretic peptide B, also known as BNP) and to
monitor tumor progression (carcinoembryonic antigen,
also known as CEA).
These 38 tests that proved to be correlated with stroke
both reproduced previously known predictors of stroke
and introduce several novel associations. The previously
known correlates include kidney dysfunction and atrial
fibrillation [25, 26].
We identified several measures of kidney function as
significant correlate of stroke. Glomerular filtration rate
is a standard measurement of renal function [27]. It is a
calculated value based upon serum levels of creatinine,
urea nitrogen, and albumin along with demographic fac-
tors: age, sex, and race [28]. Creatinine has been previ-
ously recognized as a stroke predictor [29, 30].
The stroke prediction model [3] based upon the
Cardiovascular Health Study [9] includes only one la-
boratory value, serum creatinine levels. The authors di-
vided the population into two groups, split with serum
creatinine levels above or below 1.25 mg/dL. In contrast,
we found serum creatinine levels to be a strong correlate
with continuous range from less than 0.58 mg/dL to
greater than 1.74 mg/dL as shown in Figs. 3, 4 and 5.
The BNP test is used to diagnose congestive heart fail-
ure [31]. High levels of BNP (greater than 480 pg/ml)
suggest congestive heart failure, while low levels (less
than 100 pg/ml) rule it out [32]. BNP has been shown to
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predict mortality [33, 34]. We found BNP to be a par-
ticularly good correlate of stroke even at low and inter-
mediate levels. We saw significant differences in the
prognosis for stroke even between those who had BNP
levels less than 13 pg/ml and those who tested less than
34 pg/ml.
Three parameters measured by electrocardiograms
also appear in Table 1, including the Q-T interval, the
Table 1 List of laboratory tests that were statistically significant correlates of a later diagnosis of stroke
LOINC_ID Adjusted coefficient P-value Name
2160-0 0.214 <1.0E-17 Creatinine [Mass/volume] in Serum or Plasma
2823-3 0.0725 <1.0E-17 Potassium [Moles/volume] in Serum or Plasma
4548-4 0.0163 <1.0E-17 Hemoglobin A1c/Hemoglobin.total in Blood
751-8 0.0129 <1.0E-17 Neutrophils [#/volume] in Blood by Automated count
3094-0 0.000801 <1.0E-17 Urea nitrogen [Mass/volume] in Serum or Plasma
770-8 0.000229 <1.0E-17 Neutrophils/100 leukocytes in Blood by Automated count
17865-7 0.0000519 <1.0E-17 Glucose [Mass/volume] in Serum or Plasma –8 h fasting
2345-7 0.0000315 <1.0E-17 Glucose [Mass/volume] in Serum or Plasma
27353-2 0.0000237 <1.0E-17 Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin
14957-5 0.00000201 <1.0E-17 Microalbumin [Mass/volume] in Urine
14959-1 0.00000132 <1.0E-17 Microalbumin/Creatinine [Mass Ratio] in Urine
33914-3 3.72E-15 <1.0E-17 Glomerular filtration rate/1.73 sq M.predicted by Creatinine-based formula (MDRD)
14135-8 0.000000994 2.22E-16 CD3 + CD8+ (T8 suppressor cells) cells [#/volume] in Blood
5902-2 0.00253 2.22E-16 Prothrombin time (PT) in Platelet poor plasma by Coagulation assay
42246-9 0.213 4.44E-16 Hemoglobin F/Hemoglobin.total in Blood by HPLC
742-7 0.359 8.44E-15 Monocytes [#/volume] in Blood by Automated count
711-2 2.99 8.44E-15 Eosinophils [#/volume] in Blood by Automated count
8636-3 0.0000123 6.89E-14 Q-T interval corrected
8633-0 0.0000704 1.17E-12 QRS duration
30934-4 0.00000147 3.10E-12 Natriuretic peptide B [Mass/volume] in Serum or Plasma
713-8 0.0163 7.54E-12 Eosinophils/100 leukocytes in Blood by Automated count
6768-6 0.0000145 1.38E-08 Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
8122-4 0.000000224 3.30E-08 CD3 cells [#/volume] in Blood
18518-1 0.0000775 5.97E-07 T wave axis.frontal plane Reference beat
2039-6 0.000871 0.00000895 Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
1751-7 −0.105 <1.0E-17 Albumin [Mass/volume] in Serum or Plasma
2028-9 −0.00139 <1.0E-17 Carbon dioxide
4544-3 −0.00102 <1.0E-17 Hematocrit [Volume Fraction] of Blood by Automated count
736-9 −0.000697 <1.0E-17 Lymphocytes/100 leukocytes in Blood by Automated count
2085-9 −0.000303 <1.0E-17 Cholesterol in HDL [Mass/volume] in Serum or Plasma
2951-2 −0.000219 <1.0E-17 Sodium [Moles/volume] in Serum or Plasma
13457-7 −0.0000849 <1.0E-17 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation
2089-1 −0.0000721 <1.0E-17 Cholesterol in LDL [Mass/volume] in Serum or Plasma
43396-1 −0.0000624 <1.0E-17 Cholesterol non HDL [Mass/volume] in Serum or Plasma
2093-3 −0.0000403 <1.0E-17 Cholesterol [Mass/volume] in Serum or Plasma
2500-7 −0.0000104 <1.0E-17 Iron binding capacity [Mass/volume] in Serum or Plasma
2498-4 −0.0000533 1.99E-10 Iron [Mass/volume] in Serum or Plasma
2075-0 −0.000161 4.53E-08 Chloride [Moles/volume] in Serum or Plasma
LOINC_ID is a standardized identifier for the laboratory. The adjusted coefficient indicates the change in the likelihood of stroke given a 1 % increase in lab
values. The p-value indicates the likelihood that the given correlation is due solely to chance. A negative adjusted coefficient indicates that higher test values
lower the risk of stroke
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QRS duration, and the T wave axis. Increases in both Q-T
interval and QRS duration were positively correlated with
stroke incidence. T wave axis was also more positively cor-
related as the axis shifted rightward (i.e., increased).
Of the 38 tests that were correlated with stroke, many
fell into distinct groups of similar function. Four labora-
tory tests associated with diabetes all correlated posi-
tively with stroke, which supports previous research
Table 2 Relative risk




Urea nitrogen [Mass/volume] in Serum or Plasma 5.61 5.05 6.23
Creatinine [Mass/volume] in Serum or Plasma 4.48 4.17 4.82
Natriuretic peptide B [Mass/volume] in Serum or Plasma 4.18 3.25 5.37
Prothrombin time (PT) in Platelet poor plasma by Coagulation assay 3.59 2.75 4.69
Microalbumin/Creatinine [Mass Ratio] in Urine 3.3 2.97 3.68
Glucose [Mass/volume] in Serum or Plasma 3.21 2.84 3.63
Glucose [Mass/volume] in Serum or Plasma –8 h fasting 2.89 2.61 3.19
Hemoglobin A1c/Hemoglobin.total in Blood 2.62 2.41 2.84
CD3 + CD8+ (T8 suppressor cells) cells [#/volume] in Blood 2.6 1.3 5.2
Microalbumin [Mass/volume] in Urine 2.5 2.27 2.75
Q-T interval corrected 2.28 2.03 2.55
Neutrophils/100 leukocytes in Blood by Automated count 2.17 2.01 2.35
Monocytes [#/volume] in Blood by Automated count 2.06 1.81 2.35
Neutrophils [#/volume] in Blood by Automated count 1.98 1.8 2.17
Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin 1.94 1.8 2.09
Eosinophils/100 leukocytes in Blood by Automated count 1.85 1.71 2.01
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 1.84 1.22 2.8
QRS duration 1.81 1.62 2.02
CD3 cells [#/volume] in Blood 1.75 0.87 3.49
Potassium [Moles/volume] in Serum or Plasma 1.64 1.56 1.73
T wave axis.frontal plane Reference beat 1.62 1.47 1.78
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 1.47 1.33 1.62
Hemoglobin F/Hemoglobin.total in Blood by HPLC 1.4 0.52 3.72
Iron binding capacity [Mass/volume] in Serum or Plasma 0.21 0.19 0.22
Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 0.27 0.26 0.28
Cholesterol non HDL [Mass/volume] in Serum or Plasma 0.28 0.26 0.29
Cholesterol in LDL [Mass/volume] in Serum or Plasma 0.31 0.29 0.33
Cholesterol [Mass/volume] in Serum or Plasma 0.32 0.31 0.33
Albumin [Mass/volume] in Serum or Plasma 0.33 0.31 0.36
Lymphocytes/100 leukocytes in Blood by Automated count 0.38 0.34 0.44
Hematocrit [Volume Fraction] of Blood by Automated count 0.46 0.44 0.47
Iron [Mass/volume] in Serum or Plasma 0.56 0.51 0.62
Cholesterol in HDL [Mass/volume] in Serum or Plasma 0.65 0.63 0.68
Sodium [Moles/volume] in Serum or Plasma 0.72 0.69 0.75
Chloride [Moles/volume] in Serum or Plasma 0.72 0.69 0.75
Carbon dioxide 0.78 0.75 0.82
Glomerular filtration rate/1.73 sq M.predicted by Creatinine-based formula (MDRD) a
Eosinophils [#/volume] in Blood by Automated count a
a indicates the value is incalculable due to lack of stroke events in 1st or 4th quartile
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on the subject [35]. Similarly, laboratory results that
might reflect impaired kidney function, such as cre-
atinine, urea nitrogen, and potassium, are also posi-
tively correlated with stroke chance. This also agrees
with previous work showing that patients with Chronic
Kidney Disease are associated with a higher risk of
stroke [36].
Interestingly, higher levels for non-HDL cholesterol
are significant risk factors for cardiac disease [37], but
not necessarily for stroke. The MRFIT study of 350,977
Table 3 The relationship between population percentile levels and absolute measurements of the 38 different laboratory tests
LOINC_ID 0.05 0.25 0.5 0.75 0.95 Units
Creatinine [Mass/volume] in Serum or Plasma 0.58 0.7 0.89 1.04 1.55 mg/dL
Albumin [Mass/volume] in Serum or Plasma 3 3.65 4 4.21 4.7 g/dL
Potassium [Moles/volume] in Serum or Plasma 3.5 3.8 4.1 4.3 4.8 mmol/L
Hemoglobin A1c/Hemoglobin.total in Blood 5.3 5.7 6.2 7.2 9.8 %
Neutrophils [#/volume] in Blood by Automated count 1.9 3 4.1 5.45 8.7 10^3/uL
Carbon dioxide 23 25 27 28 31 mmol/L
Hematocrit [Volume Fraction] of Blood by Automated count 32.4 37.2 40.2 43.1 47.25 %
Urea nitrogen [Mass/volume] in Serum or Plasma 8 11 15 20 39.5 mg/dL
Lymphocytes/100 leukocytes in Blood by Automated count 12.1 21.6 28.3 35 46.3 %
Cholesterol in HDL [Mass/volume] in Serum or Plasma 32 41 49 58 77 mg/dL
Neutrophils/100 leukocytes in Blood by Automated count 41.1 53.2 60.6 67.8 79 %
Sodium [Moles/volume] in Serum or Plasma 134 137 139 140 143 mmol/L
Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 56 82 104 129 170 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma 57 82 104 129 171 mg/dL
Cholesterol non HDL [Mass/volume] in Serum or Plasma 78 106 131 160 209 mg/dL
Glucose [Mass/volume] in Serum or Plasma –8 h fasting 77 87 95 104 143 mg/dL
Cholesterol [Mass/volume] in Serum or Plasma 123 155 181 210 258 mg/dL
Glucose [Mass/volume] in Serum or Plasma 73 85 94 107 179 mg/dL
Glucose mean value [Mass/volume] in Blood Estimated from glycated hemoglobin 107 120 138 167 232 mg/dL
Iron binding capacity [Mass/volume] in Serum or Plasma 246 311 354 400 471 ug/dL
Microalbumin [Mass/volume] in Urine 3.6 7.1 17.8 61.1 747.6 mg/dL
Microalbumin/Creatinine [Mass Ratio] in Urine 2.7 5.9 14.8 54.2 765.6
Glomerular filtration rate/1.73 sq M.predicted by Creatinine-based formula (MDRD) 34 58 71 80 88 mL/min/1.73 m2
CD3 + CD8+ (T8 suppressor cells) cells [#/volume] in Blood 343 597 829 1128 1768 10^9/L
Prothrombin time (PT) in Platelet poor plasma by Coagulation assay 12.1 12.7 13.3 14.2 26 seconds
Hemoglobin F/Hemoglobin.total in Blood by HPLC 0.2 0.3 0.5 0.7 2 %
Monocytes [#/volume] in Blood by Automated count 0.3 0.4 0.5 0.6 1 10^3/uL
Eosinophils [#/volume] in Blood by Automated count 0 0 0.1 0.2 0.5 10^3/uL
Q-T interval corrected 387 410 427 444 476.5 ms
QRS duration 72 82 88 96 128 ms
Natriuretic peptide B [Mass/volume] in Serum or Plasma 13 34 129 337 1099 pg/mL
Eosinophils/100 leukocytes in Blood by Automated count 0.3 1.1 2 3.2 6.4 %
Iron [Mass/volume] in Serum or Plasma 23 52 77 105 158 ug/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 40 54 67 84 145 Units/L
CD3 cells [#/volume] in Blood 744 1201 1541 1940 2755 cells/uL
Chloride [Moles/volume] in Serum or Plasma 98 102 104 105 108 mmol/L
T wave axis.frontal plane Reference beat −6 24 41 56 83 degree(angle)
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 1.1 1.6 2.5 4.8 59.7 ng/mL
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men over six years found that lower levels of total chol-
esterol lead to a higher risk of death by intracranial
hemorrhage, while higher levels did lead to an increased
risk of non-hemorrhagic stroke [38]. Men with serum
cholesterol levels less than 160 mg/dL had three
times the risk of intracranial hemorrhage compared
to those with higher cholesterol levels. The more re-
cent Physicians’ Health Study, 22,071 men followed
for 11 years, found no significant correlation between
total cholesterol, HDL cholesterol, or triglycerides and
ischemic stroke [39].
Our findings showed that higher levels of total choles-
terol, HDL, LDL, and non-HDL cholesterol were corre-
lated with significantly decreased incidence of stroke.
Although other research has shown that high HDL is
correlated with decreased risk of stroke, the research on
total cholesterol and LDL has been more mixed. Our re-
sults for these tests are highly significant, and this find-
ing is interesting because many of the patients are likely
treated with statins, which are known to reduce stroke
risk while lowering LDL and total cholesterol [40]. It is
possible that stroke risk depends on long-term choles-
terol levels, and the use of statins suddenly reduces chol-
esterol levels, thus distorting this data. However, since
we did not include medications in our assessment, we
are unable to determine what relationship treatment
might have on interpreting these findings.
The significance of the EKG correlations in our results
in unclear because the clinical assessments of the EKGs
were not available in the discrete data analyzed. It is pos-
sible that increases in the Q-T interval and QRS dur-
ation being correlated with increase in stroke was due to
underlying cardiac disease and secondary cardiac mani-
festations of that disease like bundle branch blocks or
the use of antiarrhythmic medication. The positive cor-
relation of rightward axis deviation is possibly due to
similar causes, or possibly associated with COPD and
right-sided heart failure or right ventricular hypertrophy.
Further assessment of this relationship would help clar-
ify the significance of this correlation.
The results for iron-related labs are inconsistent. High
TIBC is negatively correlated with stroke, but high iron
is also negatively correlated, although at a much lower
significance level. Since high TIBC is a better correlate,
it could imply that iron deficiency is correlated with in-
creased risk of stroke, although we would also expect
low iron in that situation. The literature on the associ-
ation of iron with stroke appears to be mixed, with a re-
cent study [41] on a specific population of patients
showing positive correlation, and other studies showing
negative [42] or mixed [43] correlations. Further analysis
of iron’s association with stroke may be helpful.
Albumin was the strongest negative correlate for
stroke in our results. This observation is consistent with
Fig. 2 This figure presents the relationship between serum cholesterol levels and the risk of stroke measured from the electronic medical records
of 2.4 million patients over a two year time span. Error bars indicate 95 % confidence intervals. The LDL levels calculated with the Friedewald
equation are known to be systematically lower than direct measurements of LDL cholesterol [49]
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Fig. 3 This figure presents Kaplan Meier survival graphs for 38 different laboratory tests. In each case, the graphs show the survival (percentage of
the population who have not been diagnosed with a stroke) as a function of time. The population is broken up into five categories
corresponding to those in the 5%, 25%, 50%, 75%, and 95%. The test values that correspond to those percentiles are given in Table 3. The 38
different survival graphs are separated into three panels: Fig 3, Fig 4, and Fig 5
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Fig. 4 This figure presents Kaplan Meier survival graphs for 38 different laboratory tests. In each case, the graphs show the survival (percentage of
the population who have not been diagnosed with a stroke) as a function of time. The population is broken up into five categories
corresponding to those in the 5%, 25%, 50%, 75%, and 95%. The test values that correspond to those percentiles are given in Table 3. The 38
different survival graphs are separated into three panels: Fig 3, Fig 4, and Fig 5
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Fig. 5 This figure presents Kaplan Meier survival graphs for 38 different laboratory tests. In each case, the graphs show the survival (percentage of
the population who have not been diagnosed with a stroke) as a function of time. The population is broken up into five categories
corresponding to those in the 5%, 25%, 50%, 75%, and 95%. The test values that correspond to those percentiles are given in Table 3. The 38
different survival graphs are separated into three panels: Fig 3, Fig 4, and Fig 5
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numerous studies that showed a beneficial effect of high
albumin on risk of stroke [44–46].
We identified common laboratory blood tests that
correlate with stroke. Some were positively associated
(neutrophil count and percent, CD3 + CD8+ T8 sup-
pressor cells, monocytes, eosinophils, and CD3 cells),
while others were negatively correlated (hematocrit,
lymphocytes). Given the numerous clinical reasons for
these blood tests to be both high and low across inpatient
and outpatient encounters, it is difficult to determine any
likely justification for the correlation from these readings.
This analysis has a number of limitations. The discrete
data used is only from a one-year time period, and may
benefit from expanding to additional years. We selected
for review only patients with KP health insurance that
was continuous, thereby limiting the assessment to only
insured patients. This selection likely underrepresents
for people that were uninsured or partially insured for
any reason. We did not include claims data to identify
KP members that were diagnosed with strokes outside
of the KP network of care or outside of this time period,
and therefore may not include all KP members that had
strokes during that timeframe or before the beginning of
the timeframe. Our method of taking the median labora-
tory value when multiple results exist during a month
may artificially normalize abnormal readings, doesn’t
fully take into account the potential impact of acute care
events, and even then isn’t necessarily independent.
Other methods exist for considering time correlations
that could be used in a similar assessment [47].
We did not include medication data in our analysis,
which could have a significant impact on some of our
findings. In particular, the significance of the cholesterol
tests on stroke is likely complicated by the high rate of
LDL control using cholesterol lowering medications, like
statins, at KP, and their ability to reduce the risk of
strokes [40, 48]. Additional analysis that factored in
medication use would likely raise additional findings for
consideration.
We included both hemorrhagic and non-hemorrhagic
strokes in our analysis, and did not differentiate between
the two. This allowed us to compare our results to
other landmark studies [1, 2]. Since the risk factors
for these two conditions are different, and the num-
ber of non-hemorrhagic strokes is significantly higher
than hemorrhagic strokes, our analysis may not accur-
ately reflect the correlation between these lab tests
and hemorrhagic strokes. Further assessment of each
sub-group would be an important area for further
analysis. Over 95 % of the strokes analyzed were non-
hemorrhagic.
We used ICD-9 diagnoses documented in the medical
record to identify patients with a stroke. Since this in-
cluded problem list diagnoses, it is possible that patients
were included that had a history of stroke and not a
current stroke event if that diagnosis was added to the
problem list during our timeframe. Also, a diagnosis of
stroke is only appropriate as an acute diagnosis, but we
did not limit our selection to only acute encounters, and
therefore could have over-selected patients into our co-
hort who had previously had strokes. We could have
limited our selection of patients to only first-time stroke
patients using more historic data, and not including pa-
tients with diagnoses representing side effects of strokes,
but did not do so.
Conclusion
In conclusion, we identified several dozen independent
laboratory tests that are strong correlates of stroke.
These laboratory tests could be combined to provide a
short-term (one year) measure of the probability that a
patient will be diagnosed with a stroke.
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